There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Mucin-1


Mucin-1 Molecule Information

Target Synonym:Episialin;Polymorphic epithelial mucin;MUC1-alpha;Peanut-reactive urinary mucin;MUC-1;Tumor-associated mucin;MUC1-CT;MUC1-beta;MUC1;Krebs von den Lungen-6;Mucin-1 subunit alpha;Mucin-1 subunit beta;Cancer antigen 15-3;CD_antigen=CD227;Breast carcinoma-ass
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:30
Lastest Research Phase:Phase ?

Mucin-1 Protein Product ListCompare or Buy

Mucin-1 Part of Bioactivity data

Human Mucin-1 (24-380), Fc TagHuman Mucin-1 (24-380), Fc Tag (Cat. No. MU1-H5254) ELISA bioactivity

Immobilized Human Mucin-1 (24-380), Fc Tag (Cat. No. MU1-H5254) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Mucin-1 Antibody, Mouse IgG1 (SM-3) with a linear range of 0.5-4 ng/mL (QC tested).

Mucin-1 Molecule Synonym Name

Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1/SEC,MUC-1/X,MUC1/ZD,PEM,PEMT,PUM,CA 15-3,Episialin

Mucin-1 Molecule Background

Mucin-1 (MUC1) is also known as Tumor-associated epithelial membrane antigen (EMA), Polymorphic epithelial mucin (PEM), Peanut-reactive urinary mucin (PUM), PEMT, Krebs von den Lungen-6 (KL-6), CD antigen CD227, Episialin, H23AG. MUC1 is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. Mucins line the apical surface of epithelial cells in the lungs, stomach, intestines, eyes and several other organs. Mucins protect the body from infection by pathogen binding to oligosaccharides in the extracellular domain, preventing the pathogen from reaching the cell surface. Except protective function by binding to pathogens, MUC1 also functions in a cell signaling capacity. Overexpression of MUC1 is often associated with colon, breast, ovarian, lung and pancreatic cancers.

Mucin-1 References

Mucin-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MUC1-Poly-ICLC MUC1-poly-ICLC,MUC1 poly ICLC Phase Ⅱ University of Pittsburgh Non small cell lung cancer (NSCLC), Colorectal cancer Details
Monoclonal antibody SM-3 Phase Ⅰ Cancer Research Technology Polycythaemia vera, Solid tumours Details
90Y Clivatuzumab Tetraxetan 90Y-hPAM4; 90hY-PAM4; IMMU-107,90YhPAM4; 90hYPAM4; IMMU107 Phase Ⅲ Immunomedics Pancreatic cancer Details
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) Phase Ⅱ University of Sydney, Guangzhou Anjie Biomedical Technology, the First Affiliated Hospital of Guangdong Pharmaceutical University Advanced non small cell lung cancer Details
Cancer vaccine MUC-1 (GlaxoSmithKline/University of Pittsburgh) Phase Ⅰ GlaxoSmithKline, University of Pittsburgh Colon cancer, Breast cancer, Pancreatic cancer Details
Monoclonal Antibody ICO25 (Russian National Cancer Research Center) ICO-25 Phase Ⅱ The Russian National Cancer Research Center, P Hertzen Moscow Cancer Research Institute Cancer Details
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) Phase Ⅰ Innovative Cellular Therapeutics Breast cancer, Lung cancer, Pancreatic cancer Details
Gly-MUC1 conjugate prostate tumor vaccine (Memorial Sloan-Kettering) Phase Ⅰ Memorial Sloan-Kettering Cancer Center, Adjuvantys Prostate cancer Details
GO-2032c GO-203-2C Phase Ⅱ Genus Oncology, Dana-Farber Cancer Institute Acute myeloid Leukemia (AML) Details
MUC1-peptide-pulsed dendritic cell vaccine (Fudan University) Phase Ⅰ Fudan University Pancreatic cancer Details
huMNC2-CAR44 huMNC2-CAR44 Phase Ⅰ Minerva Biotechnologies Breast cancer Details
Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) Phase Ⅱ Guangzhou Anjie Biomedical Technology Non small cell lung cancer (NSCLC), Prostate cancer, Esophagus cancer Details
hCTMO1 hCTMO1 Phase Ⅰ Celltech Solid tumours Details
Anti-MUC1 monoclonal antibody (OncoQuest) Anti-MUC1 AR20.5; AR20.5; mAb-AR20.5 Phase Ⅱ AltaRex, OncoQuest, ViRexx Medical Corp Pancreatic cancer Details
MX-DTPA BrE-3 Phase Ⅰ Nonindustrial source Breast cancer Details
R-1549 R-1549,R1549 Phase Ⅲ Cancer Research UK, Antisoma, Roche Gastric cancer, Ovarian cancer Details
Gatipotuzumab GT-MAB-2.5-GEX Phase Ⅱ NEMOD, Glycotope Solid tumours, Ovarian cancer Details
TG-4010 TG-4010; VV-MUC-IL2 Phase Ⅲ Transgene Non small cell lung cancer (NSCLC) Details
Breast cancer vaccine BP1 7 (Biomira) Phase Ⅰ Biomira Breast cancer Details
IMT 504 IMT-504,IMT504 Phase Ⅱ Immunotech Neuropathic pain, Rabies, Diabetes, Chronic lymphocytic leukemia (CLL), Breast cancer, HBV infection, Sepsis, Influenza virus infection, Osteoporosis Details
ONT-10 BGLP-40; L-BGLP40; ONT-10,BGLP40; LBGLP40; ONT10,BGLP 40; LBGLP 40; ONT 10 Phase Ⅰ Cascadian Therapeutics Breast cancer, Solid tumours, Ovarian cancer Details
Adenoviral MUC1 vaccine (Etubics) Ad5-MUC1; ETBX-061 Phase Ⅱ Etubics Corporation Breast cancer, Colorectal cancer, Liver cancer, Pancreatic cancer Details
Anti-PEM monoclonal antibody Phase Ⅱ Access Pharmaceuticals Breast cancer Details
Anti-PD-L1/MUC1 CAR-pNK cell therapy (PersonGen Biomedicine/Anke Biotechnology) CAR-pNK (PersonGen Biomedicine/Anke Biotechnology),CAR pNK (PersonGen Biomedicine/Anke Biotechnology) Phase Ⅱ PersonGen Biomedicine, Anke Biotechnology Solid tumours Details
CART-TnMUC1 Phase Ⅰ University of Pennsylvania, University of Minnesota, Tmunity Therapeutics Non small cell lung cancer (NSCLC), Breast cancer, Multiple myeloma (MM), Ovarian cancer, Pancreatic cancer Details
CMB-401 CMB-401; CDP-671 Phase Ⅱ Celltech Non small cell lung cancer (NSCLC), Ovarian cancer Details
Recombinant HSP-MUC1 fusion protein (Newsummit) Phase Ⅰ Shanghai Newsummit Biopharma Breast cancer Details
Anti-CD3/MUC1-armed cytokine induced killer cells Phase Ⅱ Benhealth Biopharmaceutical Gastric cancer, Breast cancer, Colorectal cancer, Lung cancer, Liver cancer, Renal carcinoma, Pancreatic cancer Details
Monoclonal antibody HMFG1 AS-1402; BTH-1704; HuHMFG-1; R-1550 Phase Ⅱ Cancer Research UK, Antisoma Pancreatic cancer Details
BP1-7-KLH BP1-7-KLH; BLP-16 Phase Ⅰ Cascadian Therapeutics Breast cancer Details
Pepscan (Antisoma) AS-109 Phase Ⅱ Antisoma Breast cancer Details

This web search service is supported by Google Inc.